Min Lu

ORCID: 0000-0003-0378-9134
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Adenosine and Purinergic Signaling
  • Chemokine receptors and signaling
  • Chemical Synthesis and Analysis
  • Immunotherapy and Immune Responses
  • Click Chemistry and Applications
  • Testicular diseases and treatments
  • T-cell and B-cell Immunology
  • Viral Infections and Vectors
  • Nanoplatforms for cancer theranostics
  • Essential Oils and Antimicrobial Activity
  • Obstructive Sleep Apnea Research
  • Urinary and Genital Oncology Studies
  • Lipid metabolism and biosynthesis
  • Neuroblastoma Research and Treatments
  • Bee Products Chemical Analysis
  • RNA modifications and cancer
  • Chemotherapy-induced organ toxicity mitigation
  • S100 Proteins and Annexins
  • interferon and immune responses
  • Sleep and Wakefulness Research
  • Cancer-related gene regulation
  • Lung Cancer Research Studies
  • Sleep and related disorders
  • Bladder and Urothelial Cancer Treatments
  • Pregnancy and Medication Impact

Fudan University
2025

Zhongshan Hospital
2025

People's Hospital of Cangzhou
2023

Merck & Co., Inc., Rahway, NJ, USA (United States)
2003-2022

Peking University
2021

Peking University Third Hospital
2021

Genomics Institute of the Novartis Research Foundation
2021

Wenzhou Medical University
2017-2019

Second Xiangya Hospital of Central South University
2015

Central South University
2015

Pharmacological activation of the STING (stimulator interferon genes)-controlled innate immune pathway is a promising therapeutic strategy for cancer. Here we report identification MSA-2, an orally available non-nucleotide human agonist. In syngeneic mouse tumor models, subcutaneous and oral MSA-2 regimens were well tolerated stimulated interferon-β secretion in tumors, induced regression with durable antitumor immunity, synergized anti-PD-1 therapy. Experimental theoretical analyses showed...

10.1126/science.aba6098 article EN Science 2020-08-21

Naïve T cells, when activated by specific antigen and cytokines, up-regulate adhesion molecules as well chemokine receptors on their surface, which allows them to migrate inflamed tissues. Human studies have shown that CXCR3 is one of the induced during cell activation. Moreover, CXCR3-positive cells are enriched at inflammatory sites in patients with autoimmune diseases such rheumatoid arthritis multiple sclerosis. In this study, we use a mouse model inflammation demonstrate required for...

10.1189/jlb.1102573 article EN Journal of Leukocyte Biology 2003-05-28

Abstract Pharmacologic antagonism of CCR5, a chemokine receptor expressed on macrophages and activated T cells, is an effective antiviral therapy in patients with macrophage-tropic HIV infection, but its efficacy modulating inflammation immunity only just beginning to be investigated. In this regard, the recruitment CCR5-bearing cells into clinical allografts hallmark acute rejection may anticipate chronic rejection, whereas conventionally immunosuppressed renal transplant homozygous for...

10.4049/jimmunol.179.4.2289 article EN The Journal of Immunology 2007-08-15

Recent data suggest that the inhibition of arginase (ARG) has therapeutic potential for treatment a number indications ranging from pulmonary and vascular disease to cancer. Thus, high demand exists selective small molecule ARG inhibitors with favorable druglike properties good oral bioavailability. In light significant challenges associated unique physicochemical previously disclosed inhibitors, we use structure-based drug design combined focused optimization strategy discover class boronic...

10.1021/acsmedchemlett.1c00195 article EN cc-by-nc-nd ACS Medicinal Chemistry Letters 2021-07-16

Comprehensive synthetic strategies afforded a diverse set of structurally unique bicyclic proline-containing arginase inhibitors with high degree three-dimensionality. The analogs that favored the Cγ-exo conformation proline improved potency over initial lead. novel reported here not only enable access to previously unknown stereochemically complex derivatives but also provide foundation for future synthesis analogs, which incorporate inherent three-dimensional character into building...

10.1021/acsmedchemlett.1c00258 article EN ACS Medicinal Chemistry Letters 2021-10-13

Abstract Purpose To investigate the effect of intraoperative remimazolam sedation on postoperative sleep quality in elderly patients after total joint arthroplasty. Methods Between May 15, 2021 and March 26, 2022, 108 (age ≥ 65 years) who received arthroplasty under neuraxial anesthesia were randomized into group (a loading dose 0.025–0.1 mg/kg followed by an infusion rate 0.1–1.0 mg/kg/h till end surgery) or routine (sedation was given patient’s requirement dexmedetomidine 0.2–0.7 μg/kg/h)....

10.1007/s00540-023-03193-5 article EN cc-by Journal of Anesthesia 2023-04-13

LONP1 is an AAA+ protease that maintains mitochondrial homeostasis by removing damaged or misfolded proteins. Elevated activity and expression of promotes cancer cell proliferation resistance to apoptosis-inducing reagents. Despite the importance in human biology disease, very few inhibitors have been described literature. Herein, we report development selective boronic acid-based using structure-based drug design as well first structures bound various inhibitors. Our efforts led several...

10.1021/acs.jmedchem.0c02152 article EN Journal of Medicinal Chemistry 2021-04-06

Anacetrapib is an inhibitor of cholesteryl ester transfer protein (CETP), associated with reduction in LDL cholesterol and increase HDL hypercholesterolemic patients. was not taken forward into filing/registration as a new drug for coronary artery diease, despite the observation ∼9% cardiovascular risk large phase III outcomes trial (REVEAL). displayed no adverse effects throughout extensive preclinical safety evaluation, major signals were observed clinical trials studying anacetrapib,...

10.1124/dmd.118.084525 article EN Drug Metabolism and Disposition 2018-12-19

There is currently no consensus on the optimal management of de novo unilateral upper tract urothelial carcinoma (UTUC) in renal transplant recipients. We aimed to compare surgical and oncological outcomes simultaneous bilateral radical nephroureterectomy (SBRNU) (URNU) determine appropriate method.Patients who developed UTUC after transplantation underwent treatment at our center were included study. Outcomes compared between SBRNU group (underwent RNU within 3 months) URNU using...

10.1177/11795549211035541 article EN cc-by-nc Clinical Medicine Insights Oncology 2021-01-01

Abstract Arginase overexpression has been associated with poor survival rates in advanced cancer patients treated Keytruda. High levels of may lead to a depletion arginine within the tumor microenvironment, inhibiting immune response. Thus, arginase inhibition potential greatly enhance immunotherapy treatment. Discovering novel inhibitors was met several challenges including analyzing/purifying extremely polar chemical matter without chromophores, synthetically challenging space, and...

10.1158/1538-7445.am2021-297 article EN Cancer Research 2021-07-01
Coming Soon ...